Skip to content
OpenCapital
Get started

Sarepta Therapeutics, Inc. SRPT Proceeds From Sale And Maturity Of Available For Sale Securities

Proceeds From Sale And Maturity Of Available For Sale Securities at other companies

Precigen logo
PrecigenPGEN
——
BridgeBio Pharma logo
BridgeBio PharmaBBIO
——

Other financials

Income statement

See full
Revenue$730.8M-1.9%
Operating income-$300.4M-961%
Net income$331.0M+174%
EPS (diluted)-$4.60-1,343%

Balance sheet

See full
Cash & equivalents$464.5M+92.8%
Total debt$198.5M-3.4%
Total equity$1.5B+31.7%
Total assets$3.2B-8.3%

Cash flow

See full
Operating cash flow-$202.7M+65.3%
CapEx$2.1M-95.2%
Free cash flow-$204.8M+67.3%

Valuation

See full
Market cap$1.76B-63.1%

Profitability

See full
Operating margin-50.8%-1.6pp
Net margin4.6%+2.4pp
FCF margin-28.7%-9.2pp

Returns & leverage

See full
Return on equity-23.6%-28.5pp
Debt / equity0.1×0.0×
Current ratio4.6×+0.6×

Where this comes from

Reported directly by Sarepta Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.

The official record: Sarepta Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sarepta Therapeutics, Inc.'s proceeds from sale and maturity of available for sale securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sarepta Therapeutics, Inc.'s proceeds from sale and maturity of available for sale securities?
Sarepta Therapeutics, Inc. (SRPT) reported proceeds from sale and maturity of available for sale securities of $38.89M in Q1 2026.
How has Sarepta Therapeutics, Inc.'s proceeds from sale and maturity of available for sale securities changed year-over-year?
Sarepta Therapeutics, Inc.'s proceeds from sale and maturity of available for sale securities decreased by 4.6% year-over-year, from $40.76M to $38.89M.
What is the long-term trend for Sarepta Therapeutics, Inc.'s proceeds from sale and maturity of available for sale securities?
Over 4 years (2021 to 2025), Sarepta Therapeutics, Inc.'s proceeds from sale and maturity of available for sale securities has grown at a -10.7% compound annual growth rate (CAGR), from $466M to $295.87M.